3-甲基-1-苯基-5-吡唑酮(HMPP)与醋酸锌反应得到配合物[Zn2(MPP)2(CH3COO)2]·H2O。通过元素分析、红外光谱、核磁共振氢谱、热重-差热和扫描电镜对配合物的组成和结构进行了表征。用循环伏安法考察了该配合物的电化学行为,发现其...3-甲基-1-苯基-5-吡唑酮(HMPP)与醋酸锌反应得到配合物[Zn2(MPP)2(CH3COO)2]·H2O。通过元素分析、红外光谱、核磁共振氢谱、热重-差热和扫描电镜对配合物的组成和结构进行了表征。用循环伏安法考察了该配合物的电化学行为,发现其电子转移是准可逆的。通过紫外光谱法研究了它与牛血清白蛋白的相互作用,发现二者通过氢键、van der Waals力结合。该配合物对Pb2+的吸附测试结果表明,在40 min内,配合物对25mg/L的Pb2+的吸附去除率达99.74%。展开更多
The protein binding constant, binding sites of the Strychnos alkaloid-strychnine and bovine serum albumin （BSA） was determined by capillary electrophoretic frontal analysis （CE-FA） for the first time. The experime...The protein binding constant, binding sites of the Strychnos alkaloid-strychnine and bovine serum albumin （BSA） was determined by capillary electrophoretic frontal analysis （CE-FA） for the first time. The experiment was carried out in a polyacrylamide-coated fused silica capillary （48.4 cm×50 μm i.d., 38.1 cm effective length） with 20 mmol/L citrate/MES buffer （pH 6.0, ionic strength 0.17）. The applied voltage was 12 kV and detection wavelength was set at 257 nm. The plateau height of the peak was employed to determine the unbound concentration of drug in BSA equilibrated sample solution based on the external drug standard in the absence of protein. The present method provides a convenient, accurate technique for the early stage of drug screening.展开更多
文摘3-甲基-1-苯基-5-吡唑酮(HMPP)与醋酸锌反应得到配合物[Zn2(MPP)2(CH3COO)2]·H2O。通过元素分析、红外光谱、核磁共振氢谱、热重-差热和扫描电镜对配合物的组成和结构进行了表征。用循环伏安法考察了该配合物的电化学行为,发现其电子转移是准可逆的。通过紫外光谱法研究了它与牛血清白蛋白的相互作用,发现二者通过氢键、van der Waals力结合。该配合物对Pb2+的吸附测试结果表明,在40 min内,配合物对25mg/L的Pb2+的吸附去除率达99.74%。
基金The authors are grateful to the National Natural Science Foundation of China(Grant No.20235020 and 20372062)for financial support.
文摘The protein binding constant, binding sites of the Strychnos alkaloid-strychnine and bovine serum albumin （BSA） was determined by capillary electrophoretic frontal analysis （CE-FA） for the first time. The experiment was carried out in a polyacrylamide-coated fused silica capillary （48.4 cm×50 μm i.d., 38.1 cm effective length） with 20 mmol/L citrate/MES buffer （pH 6.0, ionic strength 0.17）. The applied voltage was 12 kV and detection wavelength was set at 257 nm. The plateau height of the peak was employed to determine the unbound concentration of drug in BSA equilibrated sample solution based on the external drug standard in the absence of protein. The present method provides a convenient, accurate technique for the early stage of drug screening.
